ÐÂÎÅ×ÊѶ
ÓÀÀÖ¸ß60netÔìÒ©WP203A»ñÃÀ¹úFDAÊÚÓèÒ½ÖÎÌìðå´¯µÄ¹Â¶ùÒ©È϶¨
ÈÕÆÚ£º
2026Äê04ÔÂ02ÈÕ 15:03
½üÈÕ£¬ÓÀÀÖ¸ß60netÔìÒ©ÔÚÑÐÐÂÒ©WP203A£¨°¢·¨ÅµëÄ£¬afamelanotide£©»ñµÃÃÀ¹úFDAÊÚÓèµÄÒ½ÖÎÌìðå´¯£¨pemphigus£©µÄ¹Â¶ùÒ©×ʸñÈ϶¨¡£ÕƹÜÈËÕԹڼײ©Ê¿°µÊ¾£¬“Ä¿Ç°ÎÒÃÇÕý»ý¼«Íƶ¯WP203AÔÚÈ«ÇòÁìÓòµÄÐÂÒ©¿ª·¢£¬µÈ´ý¸ü¶àµÄÌìðå´¯»¼Õß¿ÉÄÜÔçÈÕÓÃÉÏÕâһеÄÒ½ÖÎÑ¡Ôñ¡£”
¹ØÓÚWP203A£¨°¢·¨ÅµëÄ£¬afamelanotide£©
ºÚËØƤÖÊËØÊÜÌ壨MCR£©ÏµÍ³ÔÚÈËÌåÖвûÑï×ŶàÖÖÉúÀíÖ°ÄÜ£¬Ô̺¬µ÷½ÚÑ×Ö¢·´Ó³¡¢ÃâÒßϵͳÏìÓ¦¡¢´úл¡¢Ê³Æ·ÉãÈëÒÔ¼°×éÖ¯½¨¸´µÈ¡£Õâ¸öϵͳÔ̺¬ÎåÖÖ·ÖÆçµÄÊÜÌå——MC1RÖÁMC5R£¬Í¨¹ý¼¤»îÌض¨µÄºÚËØƤÖÊËØÊÜÌ壬Äܹ»²ûÑïÖî¶à×÷Óã¬ÀýÈçÏ÷¼õϸ°ûÓ¦¼¤¡¢¸ÄÉÆÑ×Ö¢Çé¿ö£¬²¢Íƽø×éÖ¯½¨¸´¡£WP203AÊÇÒ»ÖֺϳɵĺÚƤÖÊËØÊÜÌ弤°º¼Á£¬ÖØҪͨ¹ý¼¤»îMC1R²ûÑïÒ½ÖÎ×÷Ó㬾ßÌå×÷ÓûúÔì²û·¢Îª£º
1.Æ¥µÐÑõ»¯Ó¦¼¤£ºÍ¨¹ýÉϵ÷ת¼Òò×ÓNrf2£¬¾ÀÕý»úÌåµÄ¿¹Ñõ»¯/Ñõ»¯Ê§ºâ£¬´Ó¶ø¼õÇáÑõ»¯Ó¦¼¤¶ÔƤ·ôµÄΣÏÕ¡£
2.µ÷½ÚÃâÒßÓëÑ×Ö¢£ºÍ¨¹ý×÷ÓÃÓÚºÚËØƤÖÊËØÊÜÌ壬һ·½ÃæÒÖÔì¶àÖÖ´ÙÑ×ϸ°ûÒò×Ó£¬ÁíÒ»·½Ãæµ÷½ÚTÁÜ°Íϸ°ûÖ°Äܲ¢ÓÕµ¼ÓµÓп¹Ñ××÷Óõĵ÷½ÚÐÔTϸ°û£¬´Ó¶ø¸´ÔÃâÒßƽºâ¡£
3.ÍƽøƤ·ôÓúºÏ£ºÀûÓúÚËØƤÖÊËØ»¯ºÏÎï¹ÌÓеÄDZÁ¦£¬ÍƽøÓɼ¬²ãËɽ⵼ÖµÄƤ·ôÀ£ÑñºÍÉ˿ڵĽ¨¸´¡£
ÔÚÃÀ¹ú£¬°¢·¨ÅµëÄÒѱ»³É¹¦ÀûÓÃÓÚÒ½Öκìϸ°ûÌìÉúÐÔÔß²ßø²¡£¨EPP£©£¬ÆäÁÙ´²ÀûÓò»½öÑéÖ¤ÁËMC1R¼¤°º¼ÁµÄ°²È«ÐÔ£¬¸üչʾ³öÏÔÖøµÄ¿¹Ñ×DZÁ¦£¬ÎªÍØÕ¹ÆäÔÚÆäËûÑ×Ö¢ÐÔºÍ×ÔÉíÃâÒßÐÔƤ·ô²¡ÖеÄÀûÓÃÌṩÁËÓÐÁ¦Ö§³Ö¡£Õâ´ÎFDAÊÚÓèµÄ¹Â¶ùÒ©×ʸñÈ϶¨£¬×÷ΪÓÀÀÖ¸ß60netÔìÒ©WP203A¿ª·¢ÁìÓòµÄÒ»²¿ÃÅ£¬½«½øÒ»²½ÎªWP203A¿ª·¢Ð¼ÁÐÍ¡¢ÐÂÊÊÓ¦Ö¢¡¢ÐÂÊг¡µÈ´´ÐÂÐÔ²¼¾ÖÌṩÓÐÁ¦Ö§³ÖÓë±£ÏÕ¡£
¹ØÓÚÌìðå´¯
Ììðå´¯ÊÇÒ»Àັ¼ûµÄÑϳÁÍþвÈËÀཡȫµÄ×ÔÉíÃâÒßÐÔƤ·ôð¤Ä¤´óðåÐÔ¼²²¡£¬ÃâÒßϵͳÃýÎóµØ¹¥»÷Ƥ·ô±í²ã£¨±íƤ£©ºÍճĤµÄϸ°û£¬µ¼ÖÂƤ·ôË®ÅݵÄÐγɡ£²û·¢Îªð¤Ä¤ºÍƤ·ôÉÏƤµÄË®Åݺ͸¯Àã¬Í¨³ £»áÑϳÁÓ°ÏìÉúÑÄÖÊÁ¿£¬ÉõÖÁ¿ÉÄÜÖÂÃü¡£ÎÞÊýÑ°³£ÐÍÌìðå´¯£¨PV£©»¼Õß×îÏȳöÏÖ¿ÚÇ»ÇÖº¦£¬Ëæºó³ÊÏÔ줷ô²¡±ä¡ £¿ÚÇ»²¡±ä³£¼ûÓÚ¼Õð¤Ä¤ºÍÑʲ¿£¬²û·¢Îª³ÖÐøÐÔ¡¢ÌÛÍ´ÐÔ¸¯ÀûòÀ£Ññ£¬ÑϳÁÓ°Ïì½øʳ £»ÉúÖ³Æ÷ð¤Ä¤ºÍÑÛ½áĤҲ¿ÉÄÜÊÜÀÛ¡£Æ¤·ô²¡±ä²û·¢ÎªËɳÚÐÔË®ðåºÍ´óð壬³£¼ûÓÚÕý³£Æ¤·ô±í±í£¬Ë®ðåÒ×·ÖÁÑ£¬ÐγÉÀ©´óÐÔ¸¯ÀÃÃ棬NikolskyÕ÷ÑôÐÔ¡£ÎÞÊý»¼ÕßÎÞðþÑ÷Ö¢×´¡£Æ¤ËðºÃ·¢ÓÚÐر³²¿¡¢Ã沿¡¢Í·²¿¡¢Ò¸ÎÑ¡¢¸¹¹É¹µ¡¢Íβ¿µÈ¡£ Ä¿Ç°Ììðå´¯¼òÖ±Çв¡ÒòÉÐδÆëȫ˵Ã÷£¬µ«ÒÅ´«¡¢ÃâÒßÓë»·¾³³É·ÖÔÚÌìðå´¯µÄ²úÉúÖвûÑï³ÁÒª×÷Óá£ÒÅ´«³É·ÖÊÇÌìðå´¯µÄÖØÒª·çÏճɷÖÖ®Ò» £»×ÔÉí¿¹ÌålgG¹¥»÷ÇÅÁ£Ð¾Ìǵ°°×Dsg1ºÍ/»òDsg3µ¼ÖÂÆäʧȥճ¸½Ö°ÄÜ£¬ÊÇÌìðå´¯·¢²¡µÄÖ÷Ìâ˼Ôì¡£
Ììðå´¯µÄÒ½ÖÎÊܵ½¸Ã²¡µÄº±¼ûÐÔ¼°²»×ãËæ»ú¶ÔÕÕÊÔÑ飨RCTs£©µÄÏ޶ȡ£ÏÖÓеÄÒ½Öμ¿Á©Ïà¶Ôµ¥Ò»£¬È«ÉíÐÔƤÖÊÀà¹Ì´¼ÒÀÈ»ÊÇÖØÒªÒ½Öμ¿Á©£¬Óë¿Ú·þÁòßòàÑßÊ»òù·ÓËáÀ໯ºÏÎÈçù·ÓËáõ¥»òù·ÓËáÄÆ£©½áºÏʹÓÃÀ´»º½â¼²²¡½øÕ¹ ¡¢Ï÷¼õ²»Á¼·´Ó³ºÍ¸´·¢Çé¿ö¡£È»¶ø£¬¸ß´ï50%µÄ»¼Õ߻Ḵ·¢£¬65%µÄ»¼Õß»á¾ÀúÓëÃâÒßÒÖÔì¼ÁÓйصÄÑϳÁ²»Á¼ÊÂÎñ£¬Ô¼°ëÊý»¼ÕßÔÚ3ÄêºóÈÔÐè³ÖÐøÀà¹Ì´¼Ò½ÖΡ£ÀûÍ×Îôµ¥¿¹Í¨¹ýÕë¶ÔBÁÜ°Íϸ°ûCD20¿¹Ô»º½âÔçÆÚ¼²²¡¹ý³Ì £»¶ÈÆÕÀûÓȵ¥¿¹×÷ΪȫÇòÊ׸öÒ½ÖγÉÈË´óðåÐÔÀàÌìðå´¯£¨BP£©µÄ°ÐÏòÒ©Îͨ¹ýÒÖÔì°×ϸ°û½éËØ-4ºÍ°×ϸ°û½éËØ-13ÐźÅͨ·»º½â¼²²¡¹ý³Ì¡£×ÛÉÏ£¬ÏÖÓÐÒ©ÎïÆÕ±é´æÔÚ»úÔìµ¥Ò»¡¢Ò׸´·¢¡¢²»Á¼·´Ó³¶àÇÒ²úÉúÂʸ߻òÒ½ÖÎÓöȸ߰ºµÄ¾ÖÏÞ[9,10]£¬ÎÞÊý»¼ÕßµÄÁÙ´²Ò½ÖÎÐèÒªÈÔÑϳÁδÂú×ã¡£
¹ØÓÚFDA¹Â¶ùÒ©È϶¨
¹Â¶ùÒ©£¨orphan drug£©ÊÇFDAΪ¼¤Àøº±¼û²¡Ò½ÖÎÒ©ÎïµÄ¿ª·¢¶øÉèÁ¢µÄÒ»ÖÖ×ʸñÈ϶¨£¬ÎªÐÂÒ©¿ª·¢ÌṩһϵÁеļ¤Àø£¬Ô̺¬´ÓÒ©Æ·ÉÏÊлñÅúºóÆðÍ·µÄ7ÄêµÄÊг¡×¨ÓªÈ¨£¨market exclusivity£©¡¢ÐÂÒ©ÉêÇ루NDA£©µÄÓÅÏÈÉóÆÀÉóÅú£¨ÓлúÓö¼Ó¿ìÒ©Æ·ÁÙ´²×êÑÓ×¢ÉÏÊеĹý³Ì£©¡¢ÁÙ´²¿ª·¢¹ý³ÌÖÐÇ×êÇÁìµ¼ÓëÖ§³Ö£¬ÒÔ¼°ÐÂÒ©×¢²áÓöȵÄÃâÈ¥£¨2025ÄêÃÀ¹úFDAÐÂÒ©×¢²áÉêÇë·ÑԼΪ3100ÍòÈËÃñ±Ò£©¡£
²Î¿¼ÆäËû»ñµÃFDA¹Â¶ùÒ©È϶¨µÄ¡¢Õë¶Ô´æÔÚÑϳÁδÂú×ãÁÙ´²ÐèÒªµÄ¼²²¡µÄÒ©Æ·Çé¿ö£¬ÒÔ¼°WiseGuy Report¡¢±´ÕÜ˹Õ÷ѯµÈ»ú¹¹µÄ¹«¿ªµ÷ÑÐÊý¾Ý£¬¹«Ë¾Ô¤ÆÚ½«À´Ò©Æ·ÉÏÊкó£¬ÓÐÍûÔÚÖйúºÍÃÀ¹úÊг¡ÊµÏÖ°ÙÒÚÈËÃñ±Ò¼¶´ËÍâÄêÏúÊÛ¡£
ÎÄÕÂתÔØ×Ô²ÆÁªÉç
²Î¿¼Îļþ
[1] Haycock J W, Rowe S J, Cartledge S, et al. Alpha-melanocyte-stimulating hormone reduces impact of proinflammatory cytokine and peroxide-generated oxidative stress on keratinocyte and melanoma cell lines[J]. J Biol Chem, 2000, 275(21):15629-36.
[2] Mehta P, Kaye W, Raymond J, et al. Prevalence of Amyotrophic Lateral Sclerosis - United States, 2015[J]. MMWR Morb Mortal Wkly Rep, 2018, 67(46):1285-1289.
[3] Wang W, Guo D Y, Lin Y J, et al. Melanocortin Regulation of Inflammation[J]. Front Endocrinol (Lausanne), 2019, 10:683.
[4] Auriemma M, Brzoska T, Klenner L, et al. alpha-MSH-stimulated tolerogenic dendritic cells induce functional regulatory T cells and ameliorate ongoing skin inflammation[J]. J Invest Dermatol, 2012, 132(7):1814-24.
[5] Bystryn J C, Rudolph J L. Pemphigus[J]. Lancet, 2005, 366(9479):61-73.
[6] Murrell D F, Dick S, Ahmed A R, et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus[J]. J Am Acad Dermatol, 2008, 58(6):1043-6.
[7] Herbst A, Bystryn J C. Patterns of remission in pemphigus vulgaris[J]. J Am Acad Dermatol, 2000, 42(3):422-7.
[8] Bohm M, Luger T. Are melanocortin peptides future therapeutics for cutaneous wound healing?[J]. Exp Dermatol, 2019, 28(3):219-224.
[9] Minder E I, Barman-Aksoezen J, Schneider-Yin X. Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders[J]. Clin Pharmacokinet, 2017, 56(8):815-823.
[10] Understanding the Unmet Needs of the Pemphigus & Pemphigoid Community. IPPF Externally-Led Patient-Focused Drug Development Meeting, January 25, 2023
[11] https://www.gelonghui.com/p/2071680
[12] https://pre.gelonghui.com/p/2502356
[13] https://www.wiseguyreports.com/cn/reports/mucous-membrane-pemphigoid-treatments-market
ÓйØÍƼö
ÍøÕ¾½¨É裺ÖÐÆó¶¯Á¦ ̨ÖÝ